Matrix-Bio Signs Metabolomics Biomarker Licensing Agreement with Quest Diagnostics for Development of Breast Cancer Recurrence Test

FORT WAYNE, IND., April 11, 2013 - - Matrix-Bio, Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive global licensing and marketing agreement for metabolomic biomarkers with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services. Under the agreement, Quest Diagnostics will have the rights to use the biomarkers for the future, potential development of a clinical lab-developed test to aid in the detection of breast cancer recurrence. Quest Diagnostics plans to independently develop